Artivion, Inc. (AORT)

Here is how Artivion (AORT) and Pacific Biosciences of California (PACB) have performed compared to their sector so far this year.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Artivion, Inc. (NYSE: AORT). In a filing disclosed on November 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Artivion stock on October 9th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account. Representative Gilbert Ray

Bridger Management LLC lifted its position in shares of Artivion, Inc. (NYSE: AORT) by 106.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 132,588 shares of the company's stock after purchasing an additional 68,288 shares during the quarter. Artivion makes up

Class A shares of the Alger Weatherbie Specialized Growth Fund underperformed the Russell 2500 Growth Index during the third quarter of 2025. Semtech Corporation (SMTC), Impinj Inc. (PI), and Artivion, Inc. (AORT) were among the top contributors to performance. SPS Commerce, Inc. (SPSC), Palomar Holdings, Inc. (PLMR), and Vertex, Inc. (VRTX) were among the top detractors from performance.

Artivion, Inc. ( AORT ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Pat MacKin Lance Berry - EVP, COO, CFO & Treasurer Conference Call Participants Lynn Lewis - Gilmartin Group LLC John McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Joseph Conway - Needham & Company, LLC, Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to the Artivion Third Quarter 2025 Earnings Call. [Operator Instructions].

Artivion (AORT) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.

Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant currency basis Net income was $6.5 million, or $0.13 per fully diluted share, and non-GAAP net income was $7.9 million, or $0.16 per fully diluted share in the third quarter of 2025 Adjusted EBITDA increased 39% to $24.6 million in the third quarter of 2025 compared to $17.7 million in the third quarter of 2024 Enrolled first patient in ARTIZEN U.S. Investigational Device Exemption trial for Arcevo ATLANTA , Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2025. "Our third quarter performance was exceptionally strong as we made progress across each of our strategic initiatives while delivering 16% constant currency revenue growth.

ATLANTA , Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and effectiveness of the Arcevo™ LSA Hybrid Stent Graft System ("Arcevo LSA") in the treatment of acute and chronic arch pathologies. The trial is designed to support the Company's forthcoming application to the U.S. Food and Drug Administration (FDA) for Premarket Approval (PMA) of Arcevo LSA.

Oppenheimer Asset Management Inc. purchased a new stake in shares of Artivion, Inc. (NYSE: AORT) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 21,513 shares of the company's stock, valued at approximately $669,000. Oppenheimer Asset Management Inc. owned approximately 0.05% of Artivion at

ATLANTA , Oct. 29, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at the Lotte New York Palace Hotel. The Company's fireside chat is scheduled to begin at 8:00 a.m.

ATLANTA , Oct. 23, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

30-day Data from the AMDS PERSEVERE Trial Demonstrates Visceral Malperfusion Resolution in 83%, and Renal Malperfusion Resolution in 74% of Affected Subjects Post-AMDS Implantation Real-World Data from the AMDS PROTECT Trial Validate Statistically Significant Positive Outcomes Demonstrated by the PERSEVERE and DARTS trials ATLANTA , Oct. 13, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its AMDS PERSEVERE and PROTECT trials were presented in Late-Breaking Science presentations at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Copenhagen, Denmark. The AMDS PERSEVERE trial presentation highlighted positive 30-day data focused on a subset of patients with visceral and renal malperfusion.

Artivion, Inc. (NYSE:AORT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 2:35 PM EDT Company Participants James Mackin - Chairman, President & CEO Lance Berry - COO, CFO & Treasurer Presentation Unknown Analyst Perfect. Great. Thanks, everyone, for being with us.

ATLANTA , Sept. 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at the Sheraton New York Times Square Hotel.

Artivion continues to outperform with double-digit revenue growth, strong clinical results, and share gains in niche cardiology markets despite a challenging med-tech environment. New products like AMDS, Nexus, and Arcevo, along with mechanical heart valve growth, underpin a robust outlook and potential for further upside. Clinical and regulatory wins, including FDA approvals and strong study results, support ongoing growth and expand Artivion's addressable market.

Artivion, Inc. (NYSE:AORT ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Lance A. Berry - Executive VP of Finance & CFO Pat MacKin - Corporate Participant Conference Call Participants Daniel Walker Stauder - Citizens JMP Securities, LLC, Research Division Destiny Alexandra Hance Buch - Ladenburg Thalmann & Co. Inc., Research Division John Glenn McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division William John Plovanic - Canaccord Genuity Corp., Research Division Dorothy Morgan - Gilmartin Group LLC Operator Good day, ladies and gentlemen, and welcome to the Artivion Second Quarter 2025 Earnings Call.